Evidence map›Paper›PMID 34399628›Full record

ArticlemBio2021

Combination Adjuvants Enhance Recombinant Protein Vaccine Protection against Fungal Infection.

Marcel Wüthrich, Hannah E Dobson, Cleison Ledesma Taira, Uju Joy Okaa, Lucas Dos Santos Dias, Marcos Isidoro-Ayza, Nikolai Petrovsky, Bruce S Klein

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Journal of fungi (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Marcel WüthrichDepartment of Pediatrics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Hannah E DobsonDepartment of Pediatrics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Cleison Ledesma Taira *Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Uju Joy Okaa *Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Lucas Dos Santos Dias *Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Marcos Isidoro-AyzaDepartment of Pediatrics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Nikolai PetrovskyVaxine, Pty. Ltd., Warradale, Australia.
Bruce S KleinDepartment of Pediatrics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
University of Wisconsin–Madison · USFlinders University · AU

Funding

PROTECTIVE IMMUNE RESPONSES TO BLASTOMYCES DERMATITIDISR01AI040996 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI KLEIN, BRUCE STEVEN, WUETHRICH, MARCEL · 1997 to 2023
$10.4M
Molecular Pathogenesis of BlastomycosisR37AI035681 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI BRUCE Steven KLEIN · 2004 to 2026
$6.9M
Comparative Biomedical Sciences Training ProgramT32OD010423 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Marulasiddappa Suresh · 2012 to 2026
$5.0M
Regulation of vaccine-induced anti-fungal Th17 cellsR01AI093553 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI WUETHRICH, MARCEL · 2011 to 2020
$4.5M
MOLECULAR PATHOGENESIS OF BLASTOMYCOSISR01AI035681 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI KLEIN, BRUCE STEVEN · 1995 to 2019
$3.9M
Novel vaccine adjuvants to counter bioterrorist threatsU01AI061142 · NIAID · FLINDERS UNIVERSITY OF SOUTH AUSTRALIA · PI PETROVSKY, NIKOLAI · 2005 to 2009
$3.5M
Special BD LSR FortessaS10OD018202 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI PATANKAR, MANISH S · 2014 to 2014
$351k
NIAID NIH HHS HHSN272200800039CNIAID NIH HHS HHSN272201400053CNIAID NIH HHS HHSN272201800044CNIAID NIH HHS R01 AI035681NIAID NIH HHS R01 AI040996NIAID NIH HHS R01 AI093553NIAID NIH HHS R37 AI035681NIAID NIH HHS U01 AI061142NIH HHS S10 OD018202NIH HHS T32 OD010423
6 · The paper itself

Abstract

The development of effective vaccines against fungal infections requires the induction of protective, pathogen-specific cell-mediated immune responses. Here, we asked whether combination adjuvants based on delta inulin (Advax) formulated with Toll-like receptor (TLR) agonists could improve vaccine protection mediated by a fungal recombinant protein, Bl-Eng2 (i.e.,

Indexed as

Adjuvants, ImmunologicAnimalsBlastomycesBlastomycosisCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleFungal VaccinesImmunity, CellularInterferon-gammaInulinMaleMiceMice, Inbred C57BLMycosesVaccines, SyntheticAdjuvants, Immunologicdelta inulinFungal VaccinesInterferon-gammaInulinVaccines, SyntheticadjuvantsfungiimmunizationT cells

Identifiers

PMID34399628
PMCPMC8406321
OpenAlexW3194131972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.